Draupnir Bio has developed a platform for exploring the glycome to develop novel therapeutics. The platform is based on array technology, protein chemistry and advanced carbohydrate chemistry. Their lead program focuses on the development of glycan mimetics for treatment of cardiovascular diseases.
Established in 2017.
